Short-course Intravenous Antibiotic Therapy of Pediatric Acute Bone and Joint Infections: A Systematic Review and Meta-analysis.

Pediatr Infect Dis JApr 27, 2026 (epub)
Clinical ResearchPediatrics

Marina Vroutsi, Alexandra Soldatou, Panagiota Psallida et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the effectiveness of short-course intravenous antibiotic therapy (≤5 days) in previously healthy children with acute bone and joint infections (BJIs). The analysis included 813 children and found a pooled odds ratio for treatment success of 1.65, indicating no significant difference compared to longer intravenous regimens. The certainty of evidence was rated low due to imprecision.

Key findings

  • Pooled odds ratio for treatment success with short-course therapy was 1.65 (95% CI: 0.46-5.98).
  • Three out of six studies were eligible for meta-analysis.
  • Statistical heterogeneity was low (I2 = 0%).
  • The certainty of evidence for treatment success was rated low.

Why it matters

Understanding the effectiveness of shorter antibiotic courses can help clinicians optimize treatment for pediatric bone and joint infections, potentially reducing hospital stays and antibiotic exposure. However, the low certainty of evidence necessitates careful consideration in clinical decision-making.

Source

Published in Pediatr Infect Dis J. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.